Novartis7d
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
Novartis15h
Career Search
Explore opportunities with Novartis below.
Novartis10d
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...
Novartis8d
My Journey to Novartis: Finding my Purpose and Passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely ...
Novartis1d
Career Search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis2d
Career Search
Job Title Sort ascending Business Location Site Date Posted Equipment Specialist (m/w/d), Kundl, Tirol, Österreich Regulär, Full time Innovative Medicines Austria Kundl Oct 18, 2024 Trainee Marketing ...
Novartis8d
Career search
Job Title Sort ascending Business Location Site Date Posted Senior Scientist - in-vivo pharmacology/oncology (Radioligand Therapy) (80-100%*) Regular, Full time Pharma Research Switzerland Basel (City ...